ArticleBMJ open gastroenterology2017
Efficacy of individualised diets in patients with irritable bowel syndrome: a randomised controlled trial.
Article in BMJ open gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02186743 (Irritable Bowel Syndrome and Food Sensitivity), which is not on this map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Irritable Bowel Syndrome and Food Sensitivity: Assessing Clinical Outcomes and Inflammatory Cellular Pathways
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Proteomic profiling in personalized nutrition: a systematic review and methodological frameworks of randomized controlled trials.Frontiers in nutrition · 2026Pooled it
- Immune-based personalized elimination diet for the treatment of irritable bowel syndrome: a double-blind randomized sham-controlled study.Gastroenterology report · 2026Article
- The role of leukocyte activation in suspected Non-IgE excipient-related COVID-19 vaccine reactions: An exploratory hypothesis-driven study of pathogenesis.Allergy and asthma proceedings · 2024Article
- The Role of Food in the Treatment of Bowel Disorders: Focus on Irritable Bowel Syndrome and Functional Constipation.The American journal of gastroenterology · 2022Article
- Best management of irritable bowel syndrome.Frontline gastroenterology · 2021Review
- "Let Food Be Thy Medicine": Diet and Supplements in Irritable Bowel Syndrome.Clinical and experimental gastroenterology · 2021Review
- Immune Activation in Functional Gastrointestinal Disorders.Gastroenterology & hepatology · 2019Article
- Diet and Irritable Bowel Syndrome.Gastroenterology & hepatology · 2018Article
- Guidelines on the management of irritable bowel syndrome: In memory of Professor Witold Bartnik.Przeglad gastroenterologiczny · 2018Article
- A leukocyte activation test identifies food items which induce release of DNA by innate immune peripheral blood leucocytes.Nutrition & metabolism · 2018Article
- Is Personalized Dietary Therapy Effective for Individuals With Irritable Bowel Syndrome?American journal of lifestyle medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundPatients with irritable bowel syndrome (IBS) are often placed on diets guided by food intolerance assays, although these have not been validated. We assessed the effects of individualised diets in patients with IBS guided by a leucocyte activation test.
methodsThis is a parallel-group, double-blind, randomised controlled trial of 58 adults with IBS seen at an academic health centre in Northeast USA. Peripheral venous blood was analysed using a leucocyte activation test; individual foods were reported to produce positive or negative results. Participants were randomised to a 4-week diet with either individualised guidance to eliminate foods with positive assay results and allow foods with negative assay results (intervention), or with individualised guidance, matched in rigour and complexity, to eliminate foods with negative assay results and allow foods with positive assay results (comparison). The primary outcome was between-group differences in the IBS Global Improvement Scale (GIS). Secondary outcomes included reductions in IBS Symptom Severity Scale (SSS) scores and increases in IBS Adequate Relief (AR) and Quality of Life (QOL) scores. An aptamer-based proteomic analysis was conducted in strong responders.
resultsThe intervention group had significantly greater increases in mean GIS score after 4 weeks (0.86 vs comparison; 95% CI 0.05 to 1.67; p=0.04) and 8 weeks (1.22 vs comparison; 95% CI 0.22 to 2.22; p=0.02). The intervention group also had significantly greater reductions in mean SSS score at 4 weeks (-61.78 vs comparison; 95% CI -4.43 to -119.14; p=0.04) and 8 weeks (-66.42 vs comparison; 95% CI -5.75 to -127.09; p=0.03). There were no significant differences between intervention and comparison groups in mean AR or QOL scores. A reduction in neutrophil elastase concentration was associated with reduced symptoms.
conclusionsElimination diets guided by leucocyte activation tests reduced symptoms. These findings could lead to insights into the pathophysiology of IBS. TRIAL REGISTRATION NUMBER: NCT02186743.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.